Dr P.J. Devereaux is a professor in the Department of Health Research Methods, Evidence, and Impact and Department of Medicine and director of the Division of Cardiology at McMaster University.
Should the management of myocardial infarction (MI) vary depending on the patient’s age?
P.J. Devereaux, MD, PhD: Age is an important factor in terms of considering both the prognosis of dying from MI but also potential reactions to medications.
You want to take into consideration the potential bleeding risk. As we get older, there may be a higher risk of bleeding. If patients have significant bleeding issues, that is going to be relevant to choices around antiplatelets and anticoagulants.
But in general most treatment is going to be the same unless, once again, there are extenuating comorbid conditions specifically related to bleeding with an older population that would make you more cautious about some of the therapies we would use in most patients with an acute MI.